Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes-Reference-Cited by-同舟云学术

Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes

Published:2023-04 Issue: Volume:149 Page:107145
ISSN:1537-1891
Container-title:Vascular Pharmacology
language:en
Short-container-title:Vascular Pharmacology

Author:

Parker William A.E.,Angiolillo Dominick J.,Rollini Fabiana,Franchi Francesco,Bonaca Marc P.,Bhatt Deepak L.,Steg Ph. Gabriel,Orme Rachel C.,Thomas Mark R.,Judge Heather M.,Sabatine Marc S.,Storey Robert F.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pharmacology,Molecular Medicine,Physiology

Reference33 articles.

1. Antithrombotic therapy for patients with chronic coronary syndromes;Parker;Heart,2021

2. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54;Parker;Heart,2016

3. Long-term use of ticagrelor in patients with prior myocardial infarction;Bonaca;New Engl. J. Med.,2015

4. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

5. Ticagrelor in patients with stable coronary disease and diabetes;Steg;N. Engl. J. Med.,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Body Mass Index and Body Weight on Plasma Concentration of Ticagrelor and Platelet Aggregation Rate in Patients with Unstable Angina in a Chinese Han Population;Reviews in Cardiovascular Medicine;2024-03-04

2. Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration;Expert Opinion on Drug Metabolism & Toxicology;2023-10-24